Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06541301

PICC-ports Versus Chest - Ports for Long Term Chemotherapy Deliverance in Oncology Patients

Central venous access devices are extensively used in oncology patients. The current standard is represented by devices inserted by direct ultrasound guided cannulation of deep veins of supra/infraclavicular area with a reservoir placed in a subcutaneous pocket of the upper chest wall ("chest-ports"). More recently, PICC (Peripherally Inserted Central Catheters)-ports have been proposed as an alternative to chest-ports.

Aim of this study is to demonstrate the non-inferiority of PICC ports compared to thoracic ports in terms of efficacy and safety.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CRO (Centro di Riferimento Oncologico), Aviano, Italy

Loading trial locations.

About this study

Central venous access devices are extensively used in oncology patients who need safe deliverance of chemotherapeutic agents and drugs, transfusion of blood and blood products, and performance of laboratory tests, in solid as well as hematologic malignancies. These devices are mostly inserted by direct ultrasound guided cannulation of deep veins of supra/infraclavicular area and the reservoir is placed in a subcutaneous pocket of the upper chest wall ("chest-ports"). More recently, PICC (Peripherally Inserted Central Catheters)-ports have been proposed as a safe and effective alternative to chest-ports, claiming lower invasiveness, easier insertion and better patients' compliance. In PICC-ports a small reservoir is placed in a subcutaneous pocket located in the mid-third of the upper arm.

Since these feelings are currently based only on limited retrospective studies, aim of this randomized multicenter trial is to demonstrate the non-inferiority of PICC ports (experimental arm) compared to thoracic ports (control arm, as the current reference standard) in terms of efficacy and safety.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥ 18 Age ≤ 75 yrs
  • Histologic diagnosis of a solid tumour
  • Need for intravenous , long term (> 3 months), intermittent chemotherapy (either adjuvant or palliative)
  • Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-2

Exclusion criteria

  • Active infections
  • Coagulopathy, defined as platelet count < 50,000/μL and/or Prothrombin time (PT)/International Normalized Ratio (INR) > 1.5
  • Chronic severe renal failure, stage 3b-4-5 or imminent need for a dialysis fistula
  • Any conditions contraindicating chemotherapy treatments, as valued by treating oncologist
  • Life expectancy < 6 months, as valued by treating oncologist
  • Inability to give an informed consent and/or history of psychiatric or addictive disorder or other medical condition that, in the opinion of the investigator, would preclude the patient from meeting the trial requirements

Treatment and study plan

PICC-port

Device

Implantation of a PICC-port device by a dedicated PICC team member following predefined evidence-based international guidelines and protocols

Chest-port

Device

Implantation of a Chest-port device by expert physicians or certified expert nurses, following predefined evidence-based international guidelines and protocols

Primary outcomes

  1. Incidence of device failures

    Time frame: 6 months

    Number of unscheduled removal of the device due to complications

Secondary outcomes

  1. Incidence of adverse events associated to device

    Time frame: 6 months

    Number of adverse events associated with the implantation and use of the device that do not necessitate its removal

Study contacts

Contact information is provided by the study sponsor or research team.

Roberto Biffi, MD

CONTACT

[email protected]

+39 02 57489710

Sponsors and collaborators

Lead sponsor

European Institute of Oncology

Other

Registry information

Official study title

PICC-ports Versus Chest - Ports for Long Term Chemotherapy Deliverance in Oncology Patients Affected by Solid Tumors. A Prospective, Randomized Multicentric, Non Inferiority, Phase III Trial.

Acronym: PICCHEST

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Aug 7, 2024
Registry last updated
Nov 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.